Fatty Liver Alliance’s Post

📣 There is no approved treatment for Acute-on-Chronic Liver Failure (#ACLF), a life-threatening condition with an extremely high sense of emergency for patients, clinicians, regulators and payers. Our pipeline includes five assets in development to address ACLF and its complications. 📍 We will be present at the #EASL congress to talk about ACLF via 3 events and 2 scientific posters: 🎤 EF CLIF and GENFIT partnership event 🎤 UNVEIL-IT® Investigator Meeting 🎤 ELPA educational training event 📊 Poster #1: blood and peritoneal metabolomics suggest VS-01 actively captures metabolites associated with ACLF 📊 Poster #2: Nitazoxanide directly protects from stress-induced cell death to alleviate liver damage in preclinical models of ACLF 👉 Read more on our Press Release: https://lnkd.in/e5FMvpdy 🎬 See the full ACLF video: https://lnkd.in/ene_QTwV EASL | The Home of Hepatology European Foundation for the Study of Chronic Liver Failure (EF CLIF) European Liver Patients' Association - ELPA #EASLCongress #Hepathology #LiverDisease #MultipleOrganFailures #RareDisease #LiverFailure #Cirrhosis

🔬🧬 Explore the latest research from the Annals of Hepatology! Dr. Shi Ouyang and team investigate the role of ZBP1 in hepatocyte pyroptosis during acute liver injury (ALI). Here's a glimpse into their findings: 📚 Title: "ZBP1 promotes hepatocyte pyroptosis in acute liver injury by regulating the PGAM5/ROS pathway" 🔍 Abstract Highlights: - ZBP1 up-regulation 🔝observed in induced hepatocytes - Silencing ZBP1 inhibited NLRP3 inflammasome activation and pyroptosis, while also reducing PGAM5 expression and ROS production. 🧬 Conclusion: ZBP1 plays a crucial role in promoting hepatocellular pyroptosis by modulating mitochondrial damage and ROS release 💥 Stay informed! Read the full study here 👇🏼 https://lnkd.in/gQD5FpmR #Hepatology #LiverInjury #ResearchInsights

Nomenclature changes were announced at the 2023 EASL Congress, shifting NASH to metabolic dysfunction-associated steatohepatitis (MASH). This has broader impacts on liver diseases, including reducing stigma, increasing disease awareness, and accelerating drug and biomarker development in hepatology. Learn more about the latest insights and updates from our MASH experts IHEP (International Hepatology Education Program): https://bit.ly/3vLfgJM #AvalereHealth #Hepatology #MedicalScience #MASH #NASH #NAFLD #GLP1

GLP-1 receptor agonists surged in 2023, with a 352% rise in prescriptions. With these treatments reshaping the obesity and diabetes landscape, hepatology experts IHEP (International Hepatology Education Program) ask what the impact could be for metabolic dysfunction-associated steatohepatitis. Learn their insights and find out how the treatment landscape is changing: https://bit.ly/3vLfgJM #AvalereHealth #Hepatology #MedicalInnovation #MASH #NASH #GLP1

GLP-1 receptor agonists surged in 2023, with a 352% rise in prescriptions. With these treatments reshaping the obesity and diabetes landscape, hepatology experts IHEP (International Hepatology Education Program) ask what the impact could be for metabolic dysfunction-associated steatohepatitis. Learn their insights and find out how the treatment landscape is changing: https://bit.ly/3vLfgJM #AvalereHealth #Hepatology #MedicalInnovation #MASH #NASH #GLP1

GLP-1 receptor agonists surged in 2023, with a 352% rise in prescriptions. With these treatments reshaping the obesity and diabetes landscape, hepatology experts IHEP (International Hepatology Education Program) ask what the impact could be for metabolic dysfunction-associated steatohepatitis. Learn their insights and find out how the treatment landscape is changing: https://bit.ly/3vLfgJM #AvalereHealth #Hepatology #MedicalInnovation #MASH #NASH #GLP1

GLP-1 receptor agonists surged in 2023, with a 352% rise in prescriptions. With these treatments reshaping the obesity and diabetes landscape, hepatology experts IHEP (International Hepatology Education Program) ask what the impact could be for metabolic dysfunction-associated steatohepatitis. Learn their insights and find out how the treatment landscape is changing: https://bit.ly/3vLfgJM #AvalereHealth #Hepatology #MedicalInnovation #MASH #NASH #GLP1

Logical from what I understand about aspirin & salicylates.

Our hepatology experts, IHEP (International Hepatology Education Program), ask what the impact of GLP-1s could be for metabolic dysfunction-associated steatohepatitis. Read their insights: https://bit.ly/3vLfgJM

Interesting news about aspirin.